INS and Hyperglycemia: The dysfunction of the β-cells may cause a reduction in insulin release and secondary acute hyperglycemia, as it was observed in the preceding 2003 SARS-CoV-1 outbreak (329), and more recently also proposed for SARS-CoV-2 (86, 126), aggravating the hyperglycemia and enabling the multiple damaging effects of high blood glucose.